The classic website will no longer be available as of June 25, 2024. Please use the modernized ClinicalTrials.gov.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study of Efficacy and Safety of Investigational Treatments in Patients With Moderate to Severe Hidradenitis Suppurativa

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03827798
Recruitment Status : Recruiting
First Posted : February 1, 2019
Last Update Posted : April 26, 2024
Sponsor:
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals )

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
The main purpose of this study is to assess preliminary efficacy and safety of CFZ533, LYS006, MAS825 , LOU064 and VAY736 in patients with moderate to severe hidradenitis suppurativa and to determine if CFZ533, LYS006, MAS825, LOU064 and VAY736 have an adequate clinical profile for further clinical development.

Condition or disease Intervention/treatment Phase
Hidradenitis Suppurativa Drug: CFZ533 Drug: Placebo to CFZ533 Drug: LYS006 Drug: Placebo to LYS006 Drug: MAS825 Drug: Placebo to MAS825 Drug: LOU064 25mg Drug: LOU064 100mg Drug: Placebo to LOU064 Drug: VAY736 Drug: Placebo to VAY736 Phase 2

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 245 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Randomized, Subject and Investigator Blinded, Placebo-controlled and Multi-center Platform Study, to Assess Efficacy and Safety of Different Investigational Drugs in Patients With Moderate to Severe Hidradenitis Suppurativa
Actual Study Start Date : February 27, 2019
Estimated Primary Completion Date : November 22, 2024
Estimated Study Completion Date : October 23, 2026

Resource links provided by the National Library of Medicine


Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: CFZ533
s.c.
 Drug: CFZ533
s.c.
Experimental: LYS006
p.o.
 Drug: LYS006
p.o.
Placebo Comparator: Placebo to CFZ533
Matching placebo (s.c.)
 Drug: Placebo to CFZ533
s.c.
Placebo Comparator: Placebo to LYS006
Matching placebo (p.o.)
 Drug: Placebo to LYS006
p.o.
Experimental: MAS825
s.c.
 Drug: MAS825
s.c.
Placebo Comparator: Placebo to MAS825
Matching placebo (s.c.)
 Drug: Placebo to MAS825
s.c.
Active Comparator: LOU064 25mg
p.o.
 Drug: LOU064 25mg
p.o.
Active Comparator: LOU064 100mg
p.o.
 Drug: LOU064 100mg
p.o.
Placebo Comparator: Placebo to LOU064
Matching placebo p.o.
 Drug: Placebo to LOU064
p.o.
Experimental: VAY736
s.c.
 Drug: VAY736
s.c.
Placebo Comparator: Placebo to VAY736
Matching placebo (s.c.)
 Drug: Placebo to VAY736
s.c.


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. simplified Hidradenitis Suppurativa Clinical Response (sHiSCR) [ Time Frame: 16 weeks ]
    Proportion of patients achieving clinical response after 16 weeks of treatment


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients with moderate to severe HS based on the number of lesions, fistulae and anatomical areas involved
  • Minimal body weight of 50 kg
  • Able to communicate well with the investigator and understand and comply with the requirements of the study, and the ability and willingness to conduct study visits as per the study schedule

Exclusion Criteria:

  • Use of other investigational drugs at the time of screening or before
  • Women physiologically capable of becoming pregnant, unless they are using highly effective methods of contraception
  • Pregnant or lactating women

Other protocol-defined inclusion/exclusion criteria may apply

Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03827798


Contacts
Layout table for location contacts
Contact: Novartis Pharmaceuticals 1-888-669-6682 novartis.email@novartis.com
Contact: Novartis Pharmaceuticals +41613241111

Locations
Show Show 44 study locations
Sponsors and Collaborators
Novartis Pharmaceuticals
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: Novartis Pharmaceuticals
ClinicalTrials.gov Identifier: NCT03827798    
Other Study ID Numbers: CCFZ533H12201BC
First Posted: February 1, 2019    Key Record Dates
Last Update Posted: April 26, 2024
Last Verified: April 2024
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided
Plan Description:

Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.

This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Novartis ( Novartis Pharmaceuticals ):
Hidradenitis suppurativa, acne inversa, platform study
Additional relevant MeSH terms:
Layout table for MeSH terms
Hidradenitis Suppurativa
Hidradenitis
Sweat Gland Diseases
Skin Diseases
Skin Diseases, Bacterial
Bacterial Infections
Bacterial Infections and Mycoses
 Infections
Skin Diseases, Infectious
Suppuration
Antibodies, Monoclonal
Immunologic Factors
Physiological Effects of Drugs